RxDoctor Payments Data

Chloe Schott

Nurse Practitioner · Salt Lake City, UTNPI 1447981188

Payments from drug & device makers

$2,270in general payments, 2019–2025

Across 136 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$715
  • Lilly USA, LLC$237
  • AstraZeneca$168
  • Novo Nordisk$122
  • Axsome Therapeutics, Inc.$97
  • Astellas Pharma US Inc$97
  • plus $835 from 22 others

What the payments were for

  • Food & beverage$2,270100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,270 in reported general payments places this provider in the 85th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$40,036
Medicare patients
195
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$45,198
OzempicSemaglutide26$32,122
FarxigaDapagliflozin Propanediol22$31,067
JardianceEmpagliflozin19$27,269
TrulicityDulaglutide19$27,255
XareltoRivaroxaban18$22,848
MounjaroTirzepatide12$18,256
QuliptaAtogepant12$15,261
MyrbetriqMirabegron19$14,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,981
SynthroidLevothyroxine Sodium52$4,254
Rosuvastatin Calcium189$2,465
Atorvastatin Calcium288$2,297
Duloxetine Hcl41$2,014
Escitalopram Oxalate130$1,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$237$45,51131 claims
PfizerEliquis$30$45,19841 claims
Novo NordiskOzempic$122$32,12226 claims
AstraZenecaFarxiga$168$31,06722 claims
Boehringer IngelheimJardiance$47$27,26919 claims
Johnson & JohnsonXarelto$59$22,84818 claims
AbbVieQulipta, Synthroid$715$19,51564 claims
Astellas Pharma US IncMyrbetriq$97$14,92819 claims
GSKTrelegy Ellipta$89$10,98113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →